IDH1 and oligodendroglioma: Therefore, the present study aims to evaluate the 1-year progression-free survival (PFS) of treatment-naïve patients with IDH wild-type astrocytic tumors, IDH-mutant astrocytic tumors, and oligodendrogliomas according to the DSC-MRI perfusion values.